Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just join our community at The Biotech Forum by clicking HERE .Today, we put AbCellera Biologics Inc. ( NASDAQ: ABCL ) in the spotlight. It is our first look at this somewhat unique developmental concern since our last article on this name ...

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Andrea Tan - Goldman Sachs Srikripa Devarakonda - Truist Securities Evan Seigerman - BMO David Martin - Bloom Burton Brendan Smith - TD Securities Operator Good afternoon, and welcome to AbCellera’s Q3 2 ...

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -21.43%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.13, delivering a surprise of 13.33%.Over the last four quarters, the company ha ...

Q3 2024 BUSINESS UPDATE COPYRIGHT © ABCELLERA NOVEMBER 4, 2024 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, includi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common shares, no par value per share ABCL The Nasdaq Stock Market FORM 10-Q _________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION RE ...

2215 Yukon St. Vancouver. BC Canada , VSC BC T 1 604 500 NEWS RELEASE AbCellera Reports Q3 2024 Business Results 11/04/2024 VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials ac ...

AbCellera (NASDAQ: ABCL ) is a market leader for antibody discovery. Building out an integrated platform for antibody discovery and development. Their platform aims to generate best-in-class antibody medicines. The company validated its technology with over 100Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (othe ...

rdegrie/E+ via Getty Images Introduction AbCellera (NASDAQ:ABCL) has dropped 47% since my last look in September. My article took a cautious tone, describing a company whose revenues were falling despite rising R&D expenditures. I concluded with a hold recommendation, recommending a "wait-and-see" strategy for prospective investors. The company’s robust cash position and technological collaborations offer reason for cautious optimism, but this must be balanced against fiscal inefficiencies and market sk ...

AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Stephen Willey - Stifel Andrea Tan - Goldman Sachs Evan Seigerman - BMO Michael Sonntag - Leerink Partners Steven Mah - TD Securities Billal Jahangiri - Truist Operator Good afternoon. And welcome to A ...

AbCellera 42 2024 BUSINESS UPDATE AUGUST 6, 2024 DISCLAIMER 2024 BUSINESS UPDAT This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, i ...